Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
We do not prescribe it based on interest alone
In the semaglutide group, 569 out of 8803 patients (6.5%) experienced a primary cardiovascular end-point event, compared to 701 out of 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80
Wegovy Pills (semaglutide) is the first and only FDA-approved GLP-1 pill for weight loss, developed by Novo Nordisk
PMID 23247506
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
US$ 29.63
US$ 24.57
US$ 23.79
US$ 25.11
US$ 29.49
US$ 27.10
US$ 29.48
US$ 26.14
